Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at help@authorea.com in case you face any issues.

Sevgi Bilgen

and 2 more

Objective: To investigate whether the use of bispectral index (BIS) monitoring would decrease total propofol consumption during the transvaginal oocyte retrieval procedure Design: Prospective, randomized, controlled, parallel-group clinical trial Setting: Operating room, postoperative recovery room Population: One hundred and thirty, American Society of Anesthesiologists (ASA) I-II patients, over age 18, undergoing transvaginal oocyte retrieval Methods: All patients were administered 2μg/kg fentanyl, and 2mg/kg propofol for the induction of anesthesia. The patients were divided into two groups. Patients in the group bolus were given 0.5 mg/kg of propofol when necessary, according to the observer’s range of motion. Patients in the group BIS were given 10 mg/kg/hour propofol infusion adjusted to keep the BIS value between 40-60. Main Outcome Measures: The primary outcome was the total dose of propofol administered per patient. The secondary outcomes were the time to reach the value of 5 on the Modified Observer’s Assessment of Alertness Sedation Scale (MOASs), the time to reach Post Anesthetic Discharge Scoring System (PADSS) ≥9 of the patients, satisfaction of the patient, and the gynecologist. Results: The amount of total propofol was higher in the group BIS than in the group bolus administered according to the patient’s clinic. There was no difference in the time to reach the value of 5 on the MOASs between the groups. The time to reach PADSS ≥9 was longer in the group BIS than in the group bolus. There was no difference between the two groups in terms of the satisfaction of the patient and the gynecologist. Conclusion: Administration of propofol as an infusion with BIS monitoring did not reduce the amount of propofol administered to patients during transvaginal oocyte retrieval. Funding: This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.